Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amval
- Development stage
- Phase 4
- Lead developer
- Novugen Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amval is a generic fixed-dose combination of amlodipine (a calcium channel blocker) and valsartan (an angiotensin II receptor antagonist) developed and manufactured by Novugen Pharma. It is administered orally as a film-coated tablet and is indicated for the treatment of essential hypertension, particularly in patients whose blood pressure is not adequately controlled by monotherapy. Amlodipine works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to vasodilation and decreased peripheral vascular resistance. Valsartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Together, these complementary mechanisms provide effective blood pressure control.
- Brand names
- Amval
- Other names
- AMVALAMVAL Film Coated TabletsAMVAL Tabletsamlodipine + valsartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Amval.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amval.